Shopping Cart
- Remove All
Your shopping cart is currently empty
Anifrolumab
Catalog No. T77432Cas No. 1326232-46-5
Alias MEDI-546, MDX-1333
Anifrolumab（MEDI-546） is a potent type I interferon (IFN) receptor antagonist, a human monoclonal antibody that targets IFN.Anifrolumab inhibits the activity of type I interferon and is used for the prevention and treatment of systemic lupus erythematosus (SLE).
Anifrolumab
Anifrolumab
Catalog No. T77432Alias MEDI-546, MDX-1333Cas No. 1326232-46-5
Anifrolumab（MEDI-546） is a potent type I interferon (IFN) receptor antagonist, a human monoclonal antibody that targets IFN.Anifrolumab inhibits the activity of type I interferon and is used for the prevention and treatment of systemic lupus erythematosus (SLE).
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $197 | In Stock | |
| 5 mg | $447 | In Stock | |
| 10 mg | $690 | In Stock | |
| 25 mg | $1,070 | In Stock | |
| 50 mg | $1,450 | In Stock | |
| 100 mg | $1,950 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Anifrolumab"
CCCP
Cited
Carbonyl Cyanide m-Chlorophenylhydrazone, Carbonyl cyanide 3-chlorophenylhydrazone
T7081555-60-2
CCCP (Carbonyl Cyanide m-Chlorophenylhydrazone) is an oxidative phosphorylation (OXPHOS) inhibitor and mitochondrial proton carrier uncoupler. CCCP inhibits the activation of STING and its downstream signaling molecules TBK1 and IRF3.
- $41
Size
QTY
CitedDeucravacitinib
BMS-986165
T146871609392-27-9
Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor for the treatment of autoimmune diseases. It blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain, inhibiting IL-12/23 and type I IFN pathways. It selectively binds to the TYK2 pseudokinase (JH2) domain with an IC50 of 1.0 nM.
- $64
Size
QTY
RO8191 Cited
RO4948191, CDM-3008
T22142691868-88-9
RO8191 (CDM-3008) (CDM-3008) is an agonist of interferon (IFN) receptor.
- $38
Size
QTY
CitedVadimezan Cited
NSC 640488, DMXAA, ASA-404, 5,6-Dimethylxanthenone-4-acetic Acid
T6273117570-53-3
Vadimezan (DMXAA) is a vascular disrupting agent, a murine STING agonist, and an inducer of cytokines such as type I IFN. Vadimezan has antitumor activity and induces a rapid cessation of blood flow in tumors without affecting blood flow in normal tissues.
- $48
Size
QTY
CitedCridanimod
XBIO-101, CMA, 10-carboxymethyl-9-acridanone
T531738609-97-1
Cridanimod (10-carboxymethyl-9-acridanone, CMA) is a potent STING agonist that directly binds to STING and triggers a strong antiviral response through the TBK1/IRF3 route.
- $30
Size
QTY
Interferon receptor inducer-1
T137362215120-36-6
Interferon receptor inducer-1 Used in the treatment of a disorder in which the induction of interferon is involved. is an interferon (IFN) receptor inducer.
- $30
Size
QTY
IFN alpha-IFNAR-IN-1 hydrochloride
T116302070014-98-9In house
IFN alpha-IFNAR-IN-1 hydrochloride is an inhibitor of the interaction between IFN-α and IFNAR, effectively inhibiting MVA-induced IFN-α responses by BM-pDCs with an IC50 of 2-8 μM.
- $41
Size
QTY
Tilorone dihydrochloride
T024427591-69-1
Tilorone dihydrochloride, an orally active interferon inducer, exhibits both antineoplastic and anti-inflammatory actions.
- $58
Size
QTY
AX-024 hydrochloride Cited
AX-024 HCl
T44031704801-24-0
AX-024 hydrochloride (AX-024 HCl) is an cytokine release inhibitor which can strongly inhibit the production of interleukin-6 (IL-6), tumor necrosis factor-α (TNFα), interferon-γ (IFN-γ), IL-10 and IL-17A.
- $52
Size
QTY
CitedGinsenoside F3 Cited
T382962025-50-7
Ginsenoside-F3 has immunoenhancing activity by regulating production and gene expression of type 1, type 2 cytokines in murine spleen cells. Ginsenoside-F3 enhances the NF-kappaB DNA binding activity induced by ConA in murine spleen cells (10 μM).
- $110
Size
QTY
CitedMonalizumab
T766911228763-95-8
Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A). Monalizumab is a humanized monoclonal antibody against NKG2A that induces IFN-γ production, thereby activating natural killer cell function. Monalizumab has antitumor activity and can be used to study neck squamous cell carcinoma (HNSCC).
- $438
Size
QTY
CP-28888
CP28888-27
T1086869938-75-6In house
CP-28888 (CP 28888-27) is an interferon inducer, a lipoamine with antitumor activity.
- $1,520
Size
QTY
Select Batch
Concentration:6.65 mg/mL
Purity:> 95%
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | Anifrolumab（MEDI-546） is a potent type I interferon (IFN) receptor antagonist, a human monoclonal antibody that targets IFN.Anifrolumab inhibits the activity of type I interferon and is used for the prevention and treatment of systemic lupus erythematosus (SLE). |
| Targets&IC50 | ISRE:0.3 nM |
| In vitro | Anifrolumab induces sustained reduction of surface IFNAR1 and abrogates STAT1 phosphorylation at a concentration of 67.7 nM for 20 minutes[1]. Anifrolumab suppresses the differentiation of B cells into plasma cells at concentrations of 1 and 10 μg/mL for 6 or 7 days[1]. Anifrolumab inhibits type I IFN-induced ISRE signaling, with IC50s ranging from 0.004 to 0.3 nM for the IFN-α subtypes, and 0.03 nM and 0.07 nM for IFN-β and IFN-ω, respectively[1].At a concentration of 67.7 nM, Anifrolumab dose-dependently inhibits IFN-α production from pDCs in response to CpG-A or DNA-IC stimulation, inhibiting 87-95% of IFN-α production[1]. |
| Alias | MEDI-546, MDX-1333 |
| Molecular Weight | 144.92 kDa |
| Cas No. | 1326232-46-5 |
Storage & Solubility Information
| Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
| Solubility Information | DMSO: 60.00 mg/mL, Sonication is recommended. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Anifrolumab | purchase Anifrolumab | Anifrolumab cost | order Anifrolumab | Anifrolumab in vitro | Anifrolumab molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.